These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11311973)

  • 21. Corticotropin-releasing factor (CRF), but not corticosterone, increases basolateral amygdala CRF-binding protein.
    Herringa RJ; Mackenrodt DB; Barlow JD; Roseboom PH; Nanda SA; Kalin NH
    Brain Res; 2006 Apr; 1083(1):21-8. PubMed ID: 16545343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corticotropin-releasing factor receptor type 1 mediates stress-induced relapse to cocaine-conditioned place preference in rats.
    Lu L; Liu D; Ceng X
    Eur J Pharmacol; 2001 Mar; 415(2-3):203-8. PubMed ID: 11275000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist.
    Baram TZ; Chalmers DT; Chen C; Koutsoukos Y; De Souza EB
    Brain Res; 1997 Oct; 770(1-2):89-95. PubMed ID: 9372207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat.
    Swiergiel AH; Takahashi LK; Kalin NH
    Brain Res; 1993 Oct; 623(2):229-34. PubMed ID: 8221104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell type-specific modifications of corticotropin-releasing factor (CRF) and its type 1 receptor (CRF1) on startle behavior and sensorimotor gating.
    Flandreau E; Risbrough V; Lu A; Ableitner M; Geyer MA; Holsboer F; Deussing JM
    Psychoneuroendocrinology; 2015 Mar; 53():16-28. PubMed ID: 25575243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
    McCarthy JR; Heinrichs SC; Grigoriadis DE
    Curr Pharm Des; 1999 May; 5(5):289-315. PubMed ID: 10213797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent anxiolytic affects after chronic administration of the CRF₁ receptor antagonist R121919 in rats.
    Gutman DA; Owens MJ; Thrivikraman KV; Nemeroff CB
    Neuropharmacology; 2011 Jun; 60(7-8):1135-41. PubMed ID: 20951149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential activation of CRF receptor subtypes removes stress-induced memory deficit and anxiety.
    Todorovic C; Radulovic J; Jahn O; Radulovic M; Sherrin T; Hippel C; Spiess J
    Eur J Neurosci; 2007 Jun; 25(11):3385-97. PubMed ID: 17553007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice.
    Risbrough VB; Hauger RL; Pelleymounter MA; Geyer MA
    Psychopharmacology (Berl); 2003 Nov; 170(2):178-87. PubMed ID: 12845406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of CRFR
    Hollis F; Sevelinges Y; Grosse J; Zanoletti O; Sandi C
    eNeuro; 2016; 3(5):. PubMed ID: 27844053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress.
    Deak T; Nguyen KT; Ehrlich AL; Watkins LR; Spencer RL; Maier SF; Licinio J; Wong ML; Chrousos GP; Webster E; Gold PW
    Endocrinology; 1999 Jan; 140(1):79-86. PubMed ID: 9886810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similar effect of CRF
    Spinieli RL; Leite-Panissi CRA
    Brain Res Bull; 2018 Mar; 137():187-196. PubMed ID: 29246866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of CRF receptor subtypes in stress-induced behavioural responses.
    Smagin GN; Dunn AJ
    Eur J Pharmacol; 2000 Sep; 405(1-3):199-206. PubMed ID: 11033327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective corticotropin-releasing factor type 1 receptor antagonist blocks conditioned fear-induced release of noradrenaline in the hypothalamic paraventricular nucleus of rats.
    Otagiri A; Wakabayashi I; Shibasaki T
    J Neuroendocrinol; 2000 Oct; 12(10):1022-6. PubMed ID: 11012844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovulatory cycle influences the stimulatory effect of stress on the expression of corticotropin-releasing factor receptor messenger ribonucleic acid in the paraventricular nucleus of the female rat hypothalamus.
    Nappi RE; Rivest S
    Endocrinology; 1995 Sep; 136(9):4073-83. PubMed ID: 7649116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of central amygdalar and bed nucleus of the stria terminalis corticotropin-releasing factor in behavioral responses to social defeat.
    Jasnow AM; Davis M; Huhman KL
    Behav Neurosci; 2004 Oct; 118(5):1052-61. PubMed ID: 15506887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of CRF2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia.
    Smagin GN; Howell LA; Ryan DH; De Souza EB; Harris RB
    Neuroreport; 1998 May; 9(7):1601-6. PubMed ID: 9631473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress.
    Pelleymounter MA; Joppa M; Ling N; Foster AC
    J Pharmacol Exp Ther; 2002 Jul; 302(1):145-52. PubMed ID: 12065711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of regional neurotransmitter receptors in corticotropin-releasing factor (CRF)-mediated modulation of fear conditioning.
    Radulovic J; Fischer A; Katerkamp U; Spiess J
    Neuropharmacology; 2000 Feb; 39(4):707-10. PubMed ID: 10728892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Traumatic Stress Promotes Hyperalgesia via Corticotropin-Releasing Factor-1 Receptor (CRFR1) Signaling in Central Amygdala.
    Itoga CA; Roltsch Hellard EA; Whitaker AM; Lu YL; Schreiber AL; Baynes BB; Baiamonte BA; Richardson HN; Gilpin NW
    Neuropsychopharmacology; 2016 Sep; 41(10):2463-72. PubMed ID: 27013358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.